EQL Pharma AB (7JK) Stock Statistics & Valuation Metrics

EQL Pharma AB has a market cap or net worth of EUR 69.28M. The enterprise value is EUR 1.10B.

Market Cap

EUR 69.28M

Enterprise Value

EUR 1.10B

EQL Pharma AB has 29,529,610 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

29,529,610

Owned by Insiders

―

Owned by Institutions

―

EQL Pharma AB’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

Return on Equity (ROE)

―

Return on Assets (ROA)

―

Return on Invested Capital (ROIC)

―

Return on Capital Employed (ROCE)

―

Revenue Per Employee

―

Profits Per Employee

-675.74K

Employee Count

13

Asset Turnover

―

Inventory Turnover

―

In the last 12 months, EQL Pharma AB had revenue of ― and earned -8.78M in profits. Earnings per share was ―.

Revenue

―

Gross Profit

6.61M

Operating Income

-7.64M

Pretax Income

―

Net Income

-8.78M

EBITDA

-7.56M

Earnings Per Share (EPS)

―

Beta

1.02

52-Week Price Change

-53.29%

50-Day Moving Average

2.02

200-Day Moving Average

3.15

Relative Strength Index (RSI)

69.86

Average Volume (3m)

―

EQL Pharma AB upcoming earnings date is Feb 04, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 05, 2026

Next Earnings Date

Feb 04, 2027

Ex-Dividend Date

―

EQL Pharma AB has ― in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of ― billion.

Cash & Marketable Securities

―

Total Debt

EUR 0.00

Net Cash

―

Net Cash Per Share

―

Tangible Book Value Per Share

―

The average price target for EQL Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

0

Revenue Growth Forecast

12.31%

EPS Growth Forecast

-133.74%